Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable Solid Tumors

NCT ID: NCT06572956

Last Updated: 2024-08-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-21
• Study Completion Date: 2025-03-01

Brief Summary

To investigate the safety and efficacy of CAR-T/CAR-NK cells in patients with recurrent or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, glioma, etc

Detailed Description

To investigate the safety and efficacy of CAR-T/CAR-NK cells in patients with recurrent or unresectable solid tumors, including pancreatic cancer, prostate cancer, breast cancer, glioma, etc.

The study was divided into five stages: screening period, single harvest period, pretreatment chemotherapy period, treatment period, observation and follow-up period after treatment.

Subjects were pretreated with FC regimen before transfusion, and the subjects who met the infusion conditions were given CAR-T/CAR-NK cell infusion 1 ~ 2 days after the completion of eluent chemotherapy. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.

The efficacy was evaluated according to the evaluation criteria for solid tumors (RECIST1.1 selection).

Conditions

Safety and Efficacy of Cellular Drugs, Objective Response Rate of Subjects, Etc

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

recurrent or unresectable solid tumors

One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.

Group Type: EXPERIMENTAL

CAR-T/CAR-NK cell injection

Intervention Type: BIOLOGICAL

One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.

Interventions

CAR-T/CAR-NK cell injection

One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Recurrent or unresectable solid tumors (including pancreatic, prostate, breast, glioma, etc.).

2. Age over 15 and under 80.

3. KPS≥50 or ECOG score ≤2 and expected survival greater than 3 months.

4. No systemic therapy (except systemic immune checkpoint suppression or activation therapy) for at least 2 weeks or at least 5 drug half-lives (whichever is shorter) prior to apheresis.

5. The absolute number of neutrophils was > 1.0x109 /L.

6. Absolute number of platelets > 50x109 /L.

7. Absolute number of lymphocytes ≥ 0.2x109 /L.

8. ALT/AST < 3 times normal value.

9. Total bilirubin < 1.5mg/dl.

10. Creatinine < 2.5mg/dl, or creatinine clearance ≥60 mL/min/1.73 m2.

11. The ejection fraction of heart ≥ 45%, echocardiography examination centerless fluid, electrocardiogram normal

12. Blood oxygen saturation ≥92% under normal environment.

13. Women of childbearing age who had a negative urine pregnancy test before dosing began and agreed to take effective contraception during the trial until the last follow-up visit.

14. Volunteer to participate in this experiment and sign the informed consent.

Exclusion Criteria

• 1) Those who are expected to survive less than 3 months. 2) Patients whose disease progression was so rapid that a complete treatment cycle could not be ensured at the time of enrollment as determined by the investigator.

3) Patients with primary tumors other than melanoma skin cancer (unless cured for more than 3 years).

4) Patients with infections including fungal, bacterial, viral or other uncontrolled infections or those requiring level 4 isolation.

5) HIV, HBV, HCV positive patients. 6) Patients with central nervous system diseases including stroke, epilepsy, dementia or autoimmune central nervous system diseases.

7) Myocardial infection, cardiac angiography or stenting, active angina pectoris or other significant clinical symptoms, or cardiogenic asthma or cardiovascular plasma cell infiltration in the 12 months prior to enrollment.

8) Those who are receiving anticoagulation therapy or have severe coagulation dysfunction.

9) The drug treatment that the patient is receiving will affect the safety and efficacy study of this project according to the judgment of the investigator.

10) Patients with allergy or history of allergy to the biologics used in this project.

11) Pregnant or lactating women. 12) Systematic use of systemic or systemic steroid drugs within 2 weeks prior to treatment (except those who have recently or currently used inhaled steroids).

13) The efficiency of T cell transduction by replication-deficient lentivirus was less than 30%, or the ability to expand in response to CD3 / CD28 costimulatory signals was insufficient (<5 times).

14) Those who have other uncontrolled diseases that the researchers consider unsuitable for enrollment.

15) Any situation that the investigator believes may increase the risk to the subject or interfere with the test results.

16) Patients who are also participating in other clinical studies.

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Second Hospital of Shandong University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shandong Province

Jinan, Shandong, China

Countries

China

Other Identifiers

2024 car-t/nk solid tumors

Identifier Type: -

Identifier Source: org_study_id